Clinical research company Medpace Holdings (NASDAQ:MEDP) in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On ...

Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours.

Rhumbline Advisers lifted its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 0.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional ...

LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Equities research analysts at William Blair decreased their Q3 2025 earnings estimates for Medpace in a research report ...

Reports Q4 revenue $536.6M, consensus $534.99M. Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, ...

Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here's a ...

Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue ...

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the ...

Narrow-moat Medpace reported mixed 2024 results. Revenue increased to $2.1 billion, up 11.8% from $1.9 billion in 2023, but the company continues to face challenges from elevated cancellation ...

Medpace expects full-year earnings to be $11.93 to $12.69 per share, with revenue in the range of $2.11 billion to $2.21 billion. This story was generated by Automated Insights ( ...

Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect. Medpace missed analysts’ revenue expectations ...